Molecular Diagnosis of Early Pancreatic Ductal Adenocarcinoma in High-Risk Patients

Wong, Theresa; Howes, Nathan; Threadgold, Jayne; Smart, Howard; Lombard, Martin; Gilmore, Ian; Sutton, Robert; Greenhalf, William; Ellis, Ian; Neoptolemos, John P.

doi:10.1159/000055852

Cited by 63 publications

(10 citation statements)

References 167 publications

(149 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For this reason, a routine procedure of pancreatic cancer screening in CP patients may not be advocated [14]. However, since patients with CP are at high risk of pancreatic cancer in the long run, the screening of pancreatic cancer with approaches of serum markers, genetic markers, and specific imaging studies may be justified in the future, especially in older (>40–50 years) patients with CP [2,43,44,45,46]. …”

Section: Discussionmentioning

confidence: 99%

Incidence of Pancreatic Cancer in Chinese Patients with Chronic Pancreatitis

Wang

Liao

et al. 2011

Pancreatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Incidence of Pancreatic Cancer in Chinese Patients with Chronic Pancreatitis

Wang

Liao

et al. 2011

Pancreatology

View full text Add to dashboard Cite

“…A family history of pancreas cancer occurs in about 5% of cases [4, 29]. An increased risk of pancreatic ductal adenocarcinoma has also been associated with several familial cancer syndromes including familial breast and ovarian cancer syndromes [30], familial atypical mole-multiple melanoma [31, 32], Peutz-Jegher’s syndrome [33], hereditary non-polyposis colon cancer [34]and ataxia telangiectasia [35]amongst others [11]. Moreover the causative mutated genes involved in these familial cancer syndromes including BRCA1, BRCA2, p16 INK4 , LKB1/STK11, hMLH2 and hMLH1 may also be found in the germline of some patients presenting with pancreatic cancer alone [7, 36, 37, 38].…”

Section: Discussionmentioning

confidence: 99%

“…Some of the early molecular events in its early pathogenesis have been discovered through the analysis of preneoplastic and early neoplastic lesions [3, 4, 5, 6, 7, 8]. Further progress has been made through the investigation of familial pancreatic cancer and cancer family syndromes in which pancreatic cancer is a variable component of the familial phenotype [9, 10, 11]. Complimenting this approach is the study of pancreatic cancer associated with cancer types that do not follow a typical pattern of inheritance.…”

Section: Introductionmentioning

confidence: 99%

Double Resection for Patients with Pancreatic Cancer and a Second Primary Renal Cell Cancer

Alexakis¹,

Bosonnet²,

Connor³

et al. 2003

Dig Surg

Self Cite

View full text Add to dashboard Cite

Background: Reports of synchronous or metachronous double kidney-pancreas cancers are very rare. Methods: We present 2 patients with renal cell carcinoma and synchronous (1 patient) or metachronous (1 patient) primary pancreatic ductal adenocarcinoma. The patients underwent resection for both cancer types with a worthwhile outcome. Results: The appearance of different primaries in an individual may indicate a genetic predisposition to different neoplasms. The study of double primary cancers is important because it might provide understanding of a shared genetic basis of different solid tumors. Conclusions: The association between these two cancers demands more detailed epidemiological and molecular investigation. From a clinical viewpoint a resectional policy is recommended.

show abstract

“…The overall prognosis for the disease is dismal: after resection, the median survival does not exceed 2 years with a 5-year survival rate less than 20% [1-3]. One major reason for this poor outcome is the late diagnosis of the disease and only about 10-20% of patients are eligible for resection [4,5]. The overall 5-year survival rate of patients with curative resection of pancreatic cancer is 25%.…”

Section: Introductionmentioning

confidence: 99%

Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2

et al. 2010

View full text Add to dashboard Cite

BackgroundPancreatic cancer has significant morbidity and mortality worldwide. Good prognosis relies on an early diagnosis. The purpose of this study was to develop techniques for identifying cancer biomarkers in the serum of patients with pancreatic cancer.MethodsSerum samples from five individuals with pancreatic cancer and five individuals without cancer were compared. Highly abundant serum proteins were depleted by immuno-affinity column. Differential protein analysis was performed using 2-dimensional differential in-gel electrophoresis (2D-DIGE).ResultsAmong these protein spots, we found that 16 protein spots were differently expressed between the two mixtures; 8 of these were up-regulated and 8 were down-regulated in cancer. Mass spectrometry and database searching allowed the identification of the proteins corresponding to the gel spots. Up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2, which have not previously been implicated in pancreatic cancer, were observed. In an independent series of serum samples from 16 patients with pancreatic cancer and 16 non-cancer-bearing controls, increased levels of mannose-binding lectin 2 and myosin light chain kinase 2 were confirmed by western blot.ConclusionsThese results suggest that affinity column enrichment and DIGE can be used to identify proteins differentially expressed in serum from pancreatic cancer patients. These two proteins 'mannose-binding lectin 2 and myosin light chain kinase 2' might be potential biomarkers for the diagnosis of the pancreatic cancer.

show abstract

Molecular Diagnosis of Early Pancreatic Ductal Adenocarcinoma in High-Risk Patients

Cited by 63 publications

References 167 publications

Incidence of Pancreatic Cancer in Chinese Patients with Chronic Pancreatitis

Incidence of Pancreatic Cancer in Chinese Patients with Chronic Pancreatitis

Double Resection for Patients with Pancreatic Cancer and a Second Primary Renal Cell Cancer

Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2

Contact Info

Product

Resources

About